Glaucoma has long been treated as a plumbing problem — too much pressure inside the eye. But a growing body of research reframes it as a slow neurodegenerative disease of the optic nerve, where intraocular pressure is one important driver among several. In this episode, Dr. Saikumar Gandapodi joins us to unpack what that shift means for patients.

We explore why some people keep losing vision even when their pressure looks controlled, and what the evidence actually shows about ocular blood flow, mitochondrial stress, and the survival of retinal ganglion cells. Dr. Gandapodi explains Netra Restoration Therapy as an integrative, adjunct approach built around neuroprotection and whole-person care.

Throughout, the conversation stays grounded: what's established, what's still emerging, and where lowering pressure remains the foundation of care. This is a research-driven look at where glaucoma treatment may be heading.

Chronic diseases of the retina and optic nerve — glaucoma, certain macular and vascular retinopathies, optic neuropathies — often progress slowly and quietly, even when pressure or blood sugar looks controlled on paper. Why does damage sometimes continue, and what determines whether these delicate neural tissues hold up over time? In this episode, Dr. Saikumar Gandapodi joins the show to explore the concept of tissue resilience: the biology that lets retinal ganglion cells and the optic nerve withstand stress.

We unpack the mechanisms that genuinely matter for these tissues — ocular blood flow and vascular dysregulation, mitochondrial energy demand, oxidative stress, neurotrophin biology, and low-grade inflammation — and separate what's well established from what's still emerging. Dr. Gandapodi explains Netra Restoration Therapy as a multi-target, adjunctive framework meant to complement, never replace, standard ophthalmic care.

Throughout, the conversation stays evidence-honest: lab findings are distinguished from animal work and from human trials, herbal and traditional-medicine concepts are translated through modern network pharmacology, and no cures are promised. This is a thoughtful look at where conventional care is strong, where it has limits, and where complementary strategies may add value.

Chronic diseases of the retina and optic nerve — glaucoma, certain macular and vascular retinopathies, optic neuropathies — often progress slowly and quietly, even when pressure or blood sugar looks controlled on paper. Why does damage sometimes continue, and what determines whether these delicate neural tissues hold up over time? In this episode, Dr. Saikumar Gandapodi joins the show to explore the concept of tissue resilience: the biology that lets retinal ganglion cells and the optic nerve withstand stress.

We unpack the mechanisms that genuinely matter for these tissues — ocular blood flow and vascular dysregulation, mitochondrial energy demand, oxidative stress, neurotrophin biology, and low-grade inflammation — and separate what's well established from what's still emerging. Dr. Gandapodi explains Netra Restoration Therapy as a multi-target, adjunctive framework meant to complement, never replace, standard ophthalmic care.

Throughout, the conversation stays evidence-honest: lab findings are distinguished from animal work and from human trials, herbal and traditional-medicine concepts are translated through modern network pharmacology, and no cures are promised. This is a thoughtful look at where conventional care is strong, where it has limits, and where complementary strategies may add value.